4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
about
Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donorsMetabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolismSteady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sexEffect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant womenComparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.HNF4α--role in drug metabolism and potential drug target?Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.Human cytochromes P450 in health and diseaseAssociation of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice.A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 inductionSignificant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.The role of african american ethnicity and metabolism in sentinel polychlorinated biphenyl congener serum levelsRegulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormoneSex differences in the expression of hepatic drug metabolizing enzymes.Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.Cytochrome P450 variations in different ethnic populations.Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease.Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers.An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite).
P2860
Q24646186-C30C99C4-EB1A-4464-A2B2-5994C394C015Q28476513-A2236277-DEBA-401F-A75E-AECC921727E3Q33683890-27A7AD80-F7B3-4631-A6FE-F6DC2741458DQ33869119-C4B9C9A3-5D27-4B1A-8953-220FD17C18DEQ33870649-1905939D-D882-463C-A1E9-83DD1B4307FEQ34311568-49C81979-5027-4944-AB87-43FBEFD2260FQ34570949-A3920C2A-979B-4197-B34C-4FE10554FB1AQ34580565-692DCC42-3341-4183-9A35-6B72BFF9359AQ35249663-AE0F6FB3-A537-41E6-9FAE-F15195CF18D3Q36072512-EBB75674-1D44-45F9-AEC6-26D1D27BDA60Q36339420-2475017D-2259-4A37-A173-096595B1F547Q36410123-B32B10C6-6BEE-4996-8657-72F280162901Q36512912-5459A650-9C2F-4960-8422-ADF4B2B78F35Q36603317-A04A8569-FD07-4EBC-961C-A350C224DE1FQ36648836-8D6B1C41-86C8-400F-B0D7-5DAB5991B510Q36729155-0DA40757-E697-4607-B7F0-D1D960E24BADQ36802040-37248955-5073-4B0A-B03B-B1EF38957FA2Q36869072-DABA2654-C6CE-4F81-A245-324612C77477Q36948140-E34FD06F-CE60-4BB8-98D4-E84911294D77Q37076544-F7672966-FD5A-4751-BF73-1B5222742FCAQ37089317-A9999EC5-FDE0-46D4-A002-8A09D38B451CQ37233832-3CACFCCA-BA47-44FB-B7A2-B20A3E3F447CQ37268108-713C91DF-99B9-43E5-9BA1-AAC22A131ACBQ37325725-586FD08B-2E6C-46E9-A5CD-EC04AFF3AA95Q37364219-EB402316-B69C-4CB7-94E1-AB0A9AE9C498Q37700667-E97B9465-2658-45E3-AED6-5CE33E93D03CQ37979866-492779A3-0CC6-446C-ABA2-B1C76197DF5CQ38133807-387E5860-668D-400B-8280-72A236E66B95Q38813488-96BB56B5-1BFA-4A62-950A-E492339F47D3Q38986439-7A4B4D57-57AD-45D9-99BA-B9CD7A73FF0EQ39478831-D58DBDC8-D858-4EED-8EC3-460CD82E2334Q39800984-E0872718-8651-4406-BB87-FA3CE8BB225DQ41328717-2CEEFB78-C786-4DB8-9BC8-D258C8EED7E8Q43144692-F22CA790-0323-4188-91E0-C11EEF274AD8Q43146767-89E0AD3F-B3D6-4226-A893-B7E12203970CQ43826505-1E007907-B924-43D7-8A20-B35829F63DF8Q45094170-F0186285-867E-432B-8CEF-FBF4CFB9B8FCQ46003084-73DCE573-C140-41E7-A4F3-1FEF8CD06925Q46495913-769E9C8E-E936-4647-B8A5-A3FA6A76A634Q47133712-174E62D2-F0D5-4CD7-B32A-361F909DFFC9
P2860
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
4Beta-hydroxycholesterol is a ...... oreans, Swedes and Tanzanians.
@en
4Beta-hydroxycholesterol is a ...... oreans, Swedes and Tanzanians.
@nl
type
label
4Beta-hydroxycholesterol is a ...... oreans, Swedes and Tanzanians.
@en
4Beta-hydroxycholesterol is a ...... oreans, Swedes and Tanzanians.
@nl
prefLabel
4Beta-hydroxycholesterol is a ...... oreans, Swedes and Tanzanians.
@en
4Beta-hydroxycholesterol is a ...... oreans, Swedes and Tanzanians.
@nl
P2093
P50
P1476
4Beta-hydroxycholesterol is a ...... oreans, Swedes and Tanzanians.
@en
P2093
Annika Allqvist
Hanna Larsson
Hyung-Keun Roh
Jong-Wook Kim
Karl G Bodin
Mary Jande
Rajaa A Mirghani
P304
P356
10.1097/FPC.0B013E3282F50EE9
P577
2008-03-01T00:00:00Z